Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Neoplasms 3Breast Neoplasms 3Prostatic Neoplasms 2Neoplasms, Nerve Tissue 2Glioma 2Glioblastoma 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Neoplasm Metastasis 1Liver Neoplasms 1Fibrosis 1Colon Cancer Liver Metastasis 1Carcinoma, Pancreatic Ductal 1Ascites 1Abdominal Neoplasms 1Abdominal Injuries 1

Interventions

Bevacizumab 3pralsetinib 2pembrolizumab 2osimertinib 2contrast agent BR1 2Pemetrexed 2Oncolytic Virotherapy 2Carboplatin 2vorasidenib 1lutetium Lu 177 dotatate 1keyhole-limpet hemocyanin 1interferon gamma-1b 1copper dotatate CU-64 1Vaccines 1Temozolomide 1Sunitinib 1Stem Cell Transplantation 1Paclitaxel 1Microbubbles 1Lutetium-177 1Lutetium 1Interleukin-12 1Interferon-gamma 1Immunotherapy 1Gemcitabine 1Cisplatin 1Biopsy 1Antibodies, Monoclonal 1AZD 6244 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms, Nerve Tissue × contrast agent BR1 × Clear all
NCT06329570 2026-04-09

Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)

NaviFUS Corporation

Phase 1/2 Recruiting
10 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Neoplasms, Nerve Tissue

NCT06496971 2026-04-09

A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients

NaviFUS Corporation

Phase 3 Recruiting
32 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Neoplasms, Nerve Tissue

Data powered by HemOnc (CC BY 4.0) Colophon âš¡